In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Hoechst, Vertex expand ICE alliance

Executive Summary

Hoechst has obtained an exclusive worldwide license from Vertex (small molecule drugs) to develop, manufacture, and market Phase I HMR 3480/VX-740 as a therapy for rheumatoid arthritis and an exclusive option for all other compounds discovered under a previous agreement.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

UsernamePublicRestriction

Register